New approaches and targets in advanced colorectal cancer
Authors:
- Teresa MacarullaTMTeresa Macarulla
- Jaume CapdevilaJCJaume Capdevila
- José Perez-GarciaJPJosé Perez-Garcia
- Francisco Javier RamosFRFrancisco Javier Ramos
- Maria Elena ElezMEMaria Elena Elez
- Ben MarkmanBMBen Markman
- Manuel Ruiz-EcharriMRManuel Ruiz-Echarri
- Josep TaberneroJTJosep Tabernero
- 30 September 2009
- journal article
- Published by Elsevier in European Journal of Cancer
- Vol. 45, 79-88
Abstract
No abstract availableThis publication has 60 references indexed in Scilit:
- Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- High Concordance of KRAS Status Between Primary Colorectal Tumors and Related Metastatic Sites: Implications for Clinical PracticeThe Oncologist, 2008
- KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experienceJournal of Clinical Oncology, 2008
- Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- KRAS Mutations As an Independent Prognostic Factor in Patients With Advanced Colorectal Cancer Treated With CetuximabJournal of Clinical Oncology, 2008
- Open-Label Phase III Trial of Panitumumab Plus Best Supportive Care Compared With Best Supportive Care Alone in Patients With Chemotherapy-Refractory Metastatic Colorectal CancerJournal of Clinical Oncology, 2007
- KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal CancerCancer Research, 2006
- Cetuximab Monotherapy and Cetuximab plus Irinotecan in Irinotecan-Refractory Metastatic Colorectal CancerNew England Journal of Medicine, 2004
- Kirsten ras Mutations in Patients With Colorectal Cancer: the Multicenter "RASCAL" StudyJNCI: Journal of the National Cancer Institute, 1998
- Prognostic markers of colorectal cancer: An evaluation of DNA content, epidermal growth factor receptor, and Ki‐67Journal of Surgical Oncology, 1992